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Abstract
Background: The efficacy of amodiaquine (AQ), sulphadoxine-pyrimethamine (SP) and the combination of SP+AQ
in the treatment of Cameroonian children with clinical malaria was investigated. The prevalence of molecular
markers for resistance to these drugs was studied to set the baseline for surveillance of their evolution with time.
Methods: Seven hundred and sixty children aged 6-59 months with uncomplicated falciparum malaria were
studied in three ecologically different regions of Cameroon - Mutengene (littoral equatorial forest), Yaoundé (forest-
savannah mosaic) and Garoua (guinea-savannah). Study children were randomized to receive either AQ, SP or the
combination AQ+SP. Clinical outcome was classified according to WHO criteria, as either early treatment failure
(ETF), late clinical failure (LCF), late parasitological failure (LPF) or adequate clinical and parasitological response
(ACPR). The occurrence of mutations in pfcrt, pfmdr1, dhfr and dhps genes was studied by either RFLP or dot blot
techniques and the prevalence of these mutations related to parasitological and therapeutic failures.
Results: After correction for the occurrence of re-infection by PCR, ACPRs on day 28 for AQ, SP and AQ+SP were
71.2%, 70.1% and 80.9%, in Garoua, 79.2%, 62.5%, and 81.9% in Mutengene, and 80.3%, 67.5% and 76.2% in
Yaoundé respectively. High levels of Pfcrt 76T (87.11%) and Pfmdr1 86Y mutations (73.83%) were associated with
quinoline resistance in the south compared to the north, 31.67% (76T) and 22.08% (86Y). There was a significant
variation (p < 0.001) of the prevalence of the SGK haplotype between Garoua in the north (8.33%), Yaoundé
(36.29%) in the savannah-forest mosaic and Mutengene (66.41%) in the South of Cameroon and a weak relation
between SGK haplotype and SP failure. The 540E mutation on the dhps gene was extremely rare (0.3%) and
occurred only in Mutengene while the pfmdr1 1034K and 1040D mutations were not detected in any of the three
sites.
Conclusion: In this study the prevalence of molecular markers for quinoline and anti-folate resistances showed
high levels and differed between the south and north of Cameroon. AQ, SP and AQ+SP treatments were well
tolerated but with low levels of efficacy that suggested alternative treatments were needed in Cameroon since
2005.
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The primary tool for the control of malaria in many
parts of Africa remains the early diagnosis and treat-
ment of clinical cases of malaria, a policy that is threa-
tened by increasing resistance of Plasmodium
falciparum to many of the cheap andp r e v i o u s l ye f f e c -
tive anti-malarial drugs, such chloroquine (CQ), amodia-
quine (AQ) and sulphadoxine-pyrimethamine (SP).
By the beginning of the twenty-first century, most
malaria infections in Cameroon were reported to be
resistant to chloroquine [1-4]. Thus, in 2002, the
Cameroonian Ministry of Health recommended a
change to the use of AQ and SP as first- and second-
line treatment for uncomplicated malaria, respectively,
with SP being used for intermittent preventive treatment
in pregnancy. In two previous studies conducted in
1998/2000 in children between five and 14 years of age
in the extreme south of Cameroon [4], clinical and para-
sitological failure rates for SP, AQ and the AQ+SP com-
bination of 13.6%, 10.2% and 0% respectively were
reported. In 2003, clinical and parasitological responses
to treatment with SP of 46.6% and 43.5% respectively
were reported in Nkambe and Mutengene in the west
and southwest of Cameroon respectively [5]. As a result,
there was an increased use of AQ alone or combined
with SP in many areas, exposing the P. falciparum
population to sub-optimal drug concentrations with the
potential for the emergence of drug resistance. Resis-
tance of P. falciparum to SP is due to point mutations
in the dihydrofolate reductase (dhfr) and dihydroptero-
ate synthase (dhps) genes [6]. The molecular mechanism
of AQ resistance in P. falciparum remains uncertain but
may be associated with mutations in the pfcrt76T and
pfmdr1 86Y genes [7,8]. To evaluate the performance of
SP, AQ, and the combination in Cameroon and to set a
baseline for monitoring the evolution of resistance, a
three-arm, double-blind randomized, efficacy and safety
study of AQ, SP, and AQ+SP for the treatment of
uncomplicated P. falciparum malaria was conducted in
young Cameroonian children in 2004-2006, with mole-
cular characterization of parasites obtained from
patients who failed treatment with these drugs.
Methods
Study design
A double-blind, randomized, controlled trial of AQ, SP
and the combination AQ+SP, in the treatment of chil-
dren with uncomplicated falciparum malaria was carried
out in three different ecological zones of Cameroon -
Mutengene (forest-littoral), Yaoundé (forest-savannah
mosaic), and Garoua (guinea-savannah) (Figure 1).
Malaria transmission at each of the three sites has two
peaks periods, at the start and at the end of the rainy
season which lasts from April to October in Mutengene
midway peri-urban town between Limbe and Tiko (EIR
= 160-287) [9] and Yaoundé urban/rural (EIR = 34-172)
[10] and from May to September in Garoua (close to a
rice farming field), similar to Goulmoun in Chad (EIR=
311) [11]. Outpatient clinics of the Cameroon Baptist
Convention, Health Board clinics and the Hôpital Jesus,
Sauve et Guérit participated in recruitment at Muten-
gene, Yaoundé and Garoua, respectively.
Participant recruitment
Informed consent for enrolment into the trial was
obtained from the parents or guardians of children aged
5-59 months, who presented to one of the study clinics
with an axillary temperature between 37.5°C and 40°C
or with a history of fever in the past 24 hours and P.
falciparum parasitaemia of between 1,000 and 200,000
parasites/μl. Children were excluded if they were unable
to tolerate oral medication, had any signs indicative of
severe or complicated malaria, had a chronic underlying
disease or had sensitivity to any of the trial medications
[9]. Children were block-randomized in 20s, using com-
puter-generated tables into three groups to receive AQ,
Figure 1 Study Sites for AQ, SP and SPAQ Efficacy in
Cameroon. Mutengene (forest-littoral), Yaoundé (forest-savannah
mosaic), and Garoua (guinea-savannah).
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was entered on to the case report form.
Treatment and follow-up
Drugs were purchased from the National Central Phar-
macy through the Cameroon Baptist Convention and
were quality controlled by the analytical laboratory in
Mutengene, Cameroon. Children in the groups who
received monotherapy, received placebos of the com-
plimentary drug purchased from Kakwa BioFarm
Accra, Ghana and matched with the active drugs for
colour and shape. The first treatment dose was admi-
nistered at the clinic by the pharmacy attendant and
repeated if the child vomited within 30 minutes of
administration. The second and third doses of treat-
ment were administered at home by the parent or
guardian. Adherence was verified on day 3 by a field
worker who asked the parent or guardian about prior
drug administration and asked to see any remaining
tablets or blisters. Doses were administered according
to a dose per weight schedule. All children were given
a single dose of paracetamol, 250 mg, 30 min before
administration of the trial drug, to control fever. Amo-
diaquine-SP was administered either as monotherapies
or as a combination at 10 mg/kg/day amodiaquine for
3 days and/or half a tablet containing 250 mg sulpha-
doxine and12.5 mg pyrimethamine for a 10 kg body
weight of SP Children were assessed either in the hos-
pital or through home visits on days 3, 7, 14, and 28,
and scored as either early treatment failure (ETF), late
clinical failure (LCF), late parasitological failure (LPF)
or adequate clinical and parasitological response
(ACPR) [12]. Rescue medication was quinine sulphate,
given in a dose of 30 mg/kg/day over a 7 day period in
line with Cameroonian National Treatment guidelines.
This drug was administered to children with persistent
symptomatic parasitaemia and to those with parasites
on day 28 regardless of fever. Filter paper sample were
collected for molecular parasitology analysis. There
were no serious adverse effects to be reported to a
Data and Safety Monitoring Board.
Laboratory analyses
Field’s stain of thick blood films was used to screen
children before recruitment when 20 high-power fields
were examined. Thick films stained with Giemsa were
used for definitive parasites counts; 200 high power
fields were screened before a slide was declared nega-
tive. The number of asexual forms of P. falciparum
per 200 leucocytes was recorded and converted into
parasite density per μl by assuming an average white
cell count of 8,000/μl. Gametocytes were counted
against 500 leukocytes. The mean of 2 slide readings
was performed and discrepancies greater than 10%
were performed by the microscopy quality assurance
expert. Haemoglobin (Hb) concentrations were mea-
sured with an electronic haemoglobin reader (Hemo-
cue®, Sweden). Parasite DNA was extracted from filter
paper using the Chelex method as described previously
[13]. Msp1, msp2 and glurp genes were amplified
through 35 rounds of PCR using primers obtained
from MR4, USA as described [14] to differentiate
between recrudescence and re-infections. PCR amplifi-
cations of the dhfr and dhps genes were performed
with primers obtained from MR4 as described by Dur-
asingh et al [15]. The PCR products were separated by
electrophoresis in a 1.5% agarose gel in the presence of
ethidium bromide. The 100 bp ladder sold by the New
England Biolabs was used as DNA size standard for
molecular size determination. The sequence-specific
oligonucleotide polymorphism (SSOP) technique was
used for molecular genotyping of point mutations of
pfcrt, pfmdr-1, dhfr and dhps genes as previously
described by Pearce et al [16]. Heat denatured (95°C
for 2 minutes), nested PCR products encompassing
polymorphisms were spotted onto nylon membranes
alongside other PCR products of known sequence
polymorphism representing all common variants of the
relevant gene. Replicate blots were made of each gene
set so that simultaneous probing with other oligonu-
cleotide probes was possible. Corresponding sequence-
specific oligonucleotide probes that were 3’-end
labelled with digoxigenin (DIG) were used for hybridi-
zation. SNP-specificity during hybridization was
e n s u r e db yh i g hs t r i n g e n c yw i t hT M A C( T e t r a m e t h y l
Ammonium Chloride) washes. Alkaline phosphatase-
conjugated anti-DIG Fab fragments were used to
detect DIG-labelled probes as described by Conway et
al [17]. Visualization was performed by enhanced che-
mifluorescence and detected on a phosphoimager
(Molecular Dynamics Storm 840; Amersham Pharma-
cia Biotech). The presence or absence of the sequence
polymorphism was scored after adjusting for back-
ground. Samples were scored as mixed haplotypes
when the value of the intensity of the reaction of a
SNP was about half that of the majority positive SNP.
Mixed haplotypes of equal strength were discarded in
frequency calculations in favour of either a single or
majority type. This principle was used both for dhfr
and dhps genes. Indeterminate samples by dot blot of
dhfr or dhps were restriction digested for the RFLP
[13,15] and re-scored.
Statistical analysis
Data were double entered into a database created with
Microsoft Access and discordances were resolved before
range and consistency checks were performed. An
Exploratory Data Analysis (EDA) was done to provide
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geometric mean, median, standard deviation, range, 95%
CI values). PCR-adjusted parasitological cure rates
between the treatment arms were compared using c
2
test. The association between various covariates (age,
gender, ethnicity, genetic markers for drug resistance)
and therapeutic outcome was performed by a multiple
logistic regression model in which progressive selection
of significant parameters and the interactions between
the different covariates were investigated. These models
took into account the different ecological zones where
the trial was conducted to examine geographical differ-
ences in response rates. The Mantel Haenszel test was
used when necessary for stratification, The Kruskal
Wallis test was used when continuous variables (such as
parasitaemia) where not normally-distributed. MicroSoft
Excel 2003 was used for producing graphs.
Ethics
Ethical approval for the study was obtained from the
Institution Review Board of the Cameroon Baptist Con-
vention Health Board, the national ethics committee of
the Ministry of Health, Cameroon and from the Ethics
Review Committee of the London School of Hygiene
and Tropical Medicine. The interests of the patients
were guarded by a local safety monitor and by an inter-
national Data and Safety Monitoring Board. The trial
was registered on the NIH clinical trials database by
number-NCT00146718.
Results
Patient characteristics
A total of 3,183 children were screened of whom 760
were eligible for inclusion in the trial. These children
were randomized and enrolled across all three sites.
About three quarters of the participants were excluded
on the basis of severe malaria (17.4%), parasite negativity
(37.6%), residence outside the study area (17.1%), fresh
scarification marks (3.6%), less than six months of age
(19.5%) and refusal of consent (5.8%). Two hundred and
f i f t yf i v ec h i l d r e nw e r ea l l o c a t e dt or e c e i v eS P ,2 5 3t o
received AQ and 252 to receive SP+AQ (Figure 2). The
mean age at enrollment (27-30 months) was similar at
each site and between study groups (Table 1). The
mean weight per group varied between 10.7 kg and 13.0
kg, with children in Garoua being on average lighter
than those from the other sites. Mean parasite density
was higher in Mutengene (the forest-littoral zone) than
at the other two sites. The prevalence of fever at enrol-
ment was 99%, 97% and 77% in Mutengene, Yaoundé
and Garoua respectively. Weakness, loss of appetite and
vomiting were the other most frequently recorded
symptoms at each site during screening.
Safety, clinical and parasitological outcomes
Follow-up rates were high with 93.1%, 93.5% and 89.2%
of children completing the 28 days of follow up in
Mutengene, Yaoundé and Garoua respectively (Figure
2). No serious adverse events were reported with the
Figure 2 Number of subjects screened, recruited and followed up by treatment group.
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received AQ. Adverse events (Table 2) were considered
to be mild to moderate and similar to malaria symp-
toms. All resolved without sequelae within the 28-day
follow-up period. After correction for re-infection by
PCR, (ACPRs) on day 14 for AQ, SP and AQ+SP
respectively, were 72.0%, 71.0%, and 81.7% in Garoua,
88.3%, 75.3% and 82.5% in Mutengene and 82.3%, 86.3%
and 88.0%, in Yaoundé (Table 3). By D28, the ACPRs
for AQ, SP and AQ+SP respectively were 71.2%, 70.1%
and 80.9% in Garoua, 79.2%, 62.5% and 81.9% in Muten-
gene and 80.3%, 67.5% and 76.2% in Yaoundé, respec-
tively (Table 3). The efficacy of SP did not differ
significantly between sites (p = 0.14). However the effi-
cacy of SP at all sites was lower than that for AQ or SP
+AQ (P < 0.05 for all sites combined). Gametocytaemia
was detected on day 7 more frequently in children trea-
t e dw i t hS Pt h a ni nt h o s et r e a t e dw i t hA Qo rA Q + S P ,
percentages being 13.9%, 5.0% and 2.4% respectively in
Mutengene, 14.5%, 7.1%, and 8.9% in Yaoundé and
2.9%, 0.0% and 1.4% in Garoua (p < 0.05). Haemoglobin
concentration rose from a mean of 8.53 ± 1.72 g/dL at
enrollment to a mean of 10.56 ± 1.26 g/dL at day 28
across all sites combined with no differences between
groups.
Molecular markers of resistance
The prevalence of mutations associated with resistance
in the pfcrt, pfmdr, dhfr and dhps genes in initial blood
samples obtained at Mutengene, Yaoundé and Garoua
respectively are shown in Figure 3. Although in vivo stu-
dies suggest no difference in failure rates, between the
sites results of molecular markers portray that parasites
in the north of the country were less mutant for both
the 76T and 86Y respectively of Pfcrt and Pfmdr1 genes
as well as for dhps and dhfr than parasites in the south.
Except for the weak relation between SP failure and the
significant variation (p < 0.001) of the prevalence of the
SGK haplotype between Garoua in the north (8.33%),
Yaoundé (36.29%) in the savannah-forest mosaic and
Mutengene (66.41%) in the South of Cameroon (Figure
3), no other associations were found between the preva-
lence of other resistance mutations at recruitment and
subsequent treatment failure at any of the study sites.
The 540E dhps mutation was detected in 2 cases in
Mutengene and nowhere else. The pfmdr1 1034K and
1040D mutations were not detected in any of the three
sites.
Discussion
This trial showed that between 2004 and 2006, SP, AQ
and AQ+SP were no longer effective enough in the
treatment of uncomplicated falciparum malaria in
Cameroon; SP failing more frequently than AQ or AQ
+SP. Cameroon is an area known to harbour parasites
with a high level of resistance to chloroquine and this
study adds SP and AQ to the list of failing anti-malaria
drugs. Although AQ and SP gave satisfactory results up
to the late 90’s [6], The findings confirm the rapid pro-
gression of resistance to SP and AQ between 2001 and
2004 in Cameroon that has been noted by others
[18-20]. SP has the potential to further the transmission
of resistant parasites by increasing the carriage of game-
tocytes with subsequent transmission of resistant strains
[21,22]. The study demonstrates that the markers of
resistance are different between the north and the south
of Cameroon. Differences in frequencies of these
Table 1 Baseline characteristics at enrollment of study children by study site
Site Mut Yao Gar
Drug Groups SPAQ SP AQ SPAQ SP AQ SPAQ SP AQ
Age (mean in months ± SD) 29 ± 15.5 27 ± 14.8 27 ± 15.2 29.4 ± 14.5 30 ± 15.1 29 ± 13.8 27 ± 15.4 26.6 ± 16.5 27.4 ± 17.2
Female/Male ratio 1 0.9 1 0.7 1.2 0.82 0.74 0.82 1.2
Weight (kg) (mean ± SD) 12.5 ± 3.5 12.2 ± 3.2 12.2 ± 4.1 13.02 ± 3.0 12.6 ± 3.4 12.9 ± 3.2 10.84 ± 3.3 10.86 ± 2.7 10.59 ± 3.3
Geo mean parasitemia (± SD) 39601
(± 48160)
27014
(± 49560)
22072
(± 30260)
7776
(± 27120)
6721
(± 25200)
5364
(± 25720)
7264
(± 27730)
5668
(± 19040)
6294
(± 26890)
Temp °C (mean ± SD) 38.9 ± 1.1 38.7 ± 1.1 38.7 ± 1.0 38.2 ± 1.2 38.3 ± 1.0 38.4 ± 1.2 37.9 ± 0.6 38.0 ± 0.6 37.7 ± 0.7
A, B, C, were groups to which independently at each site drugs were randomly assigned. SP- Sulphadoxine-pyrimethamine, AQ - Amodiaquine, SPAQ-
combination of AQ and SP, SD- Standard Deviation. Ecotypes; Mutengene (Mut) is in the littoral-forest, Yaoundé (Yao) is in the forest-savannah mosaica n d
Garoua (Gar) is in the guinnea-savannah
Table 2 Frequency of common adverse events
Drug Adverse Events Frequency
SPAQ Weakness 1.25%
Cough 1.25%
Rashes 0.84%
SP Weakness 1.25%
Cough 1.25%
Rashes 0.84%
Anorexia 0.84%
Diarrhea 1.25%
AQ Weakness 02.5%
Cough 0.42%
Rashes 0.42%
Frequencies represented here were calculated across all study sites and
represent those whose frequencies exceeded 0.
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resistance rather themselves being considered as indica-
tive of failures. There may be ethnographic or drug
pressure differences between the sites that favour higher
mutation rates in the south where there is great parasite
mixing due to higher transmissions than in the dryer
north. Unlike studies in the east of Africa that demon-
strated the presence of the 540E mutation on the dhps
[13,15] this was almost absent (identified only in 2 out
of the multitude of samples). This mutation that makes
the quintuple mutant so described by others [13,15] for
resistance to SP may not be contributing to SP
resistance in Cameroon, Central Africa, suggesting that
other genes may be involved.
In this study SP, AQ and their combination were gen-
erally well tolerated with the main reported side effects
being complaints of fatigue in children who received
AQ that resolved by D14 and D28. Adverse events were
noted if they worsened from D0 or appeared after inclu-
sion. Most of the events described by Olliaro et al [23]
were only observed with limited frequency post-therapy
as indicated under results and may be due to low num-
bers in this study as well as the fact that the study was
c o n d u c t e di nc h i l d r e nu n d e rt h ea g eo f5w h oc a n n o t
Table 3 Clinical and parasitological outcomes by site and treatment group
Mutengene Yaounde Garoua
Treatment group SPAQ SP AQ SPAQ SP AQ SPAQ SP AQ
ETF 4 14 3 0 8 1 3 10 10
L C F 2742 1 2 4251
LPF 6 11 6 10 12 8 6 7 8
ACPR, D14 (PCR corrected) 82.5% 75.3% 88.3% 82.3% 88.0% 86.3% 81.7% 71.0% 72.0%
ACPR, D28 (PCR corrected) 81.9% 62.5% 79.2% 76.2% 67.5% 80.3% 80.9% 70.1% 71.2%
Gametocyte D3 1 10 3 9 7 4 0 1 1
Carriage(n) D7 2 11 4 7 14 6 0 2 1
D 1 4 0603 1 6 0010
D 2 8 010040000
% 2.4% 13.9% 5.0% 8.9% 14.5% 7.1% 0.0% 2.9% 1.4%
A, B, C, were groups to which independently at each site drugs were randomly assigned. SP- Sulphadoxine-pyrimethamine, AQ - Amodiaquine, SPAQ-
combination of AQ and SP. ETF - Early Treatment Failure, LCF - Late Clinical Failure, LPF- Late Parastological Failure, ACPR - Adequate Clinical and Parasitological
Response.
Figure 3 Prevalence of anti-malarial drug resistance markers in Cameroon. T represents the threonine (T) mutation on codon 76 (76T) of
the Pfcrt gene. Y represents tyrosine (Y) mutation at codon 86 (86Y) of the Pfmdr1 gene as putative markers for Amodiaquine failure (AQF
(D28)). Sulphadoxine-pyrimethamine failure (SPF (D28)) whose molecular markers, IRN represents the isoleucine, arginine and asparagine
mutations at codons 51, 59 and 108 (IRN) of the dhfr gene and SGK represents the serine, glycine and lysine mutations at codon 436, 437 and
540 of the dhps gene:
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bination of AQ+SP caused no additional adverse events
to those usually ascribed to the individual component
drugs [23]. AQ and an AQ+SP combination were found
to be tolerated. Except for SP, the study treatments
were not directly observed and efficacy might have been
reduced by lack of compliance with some regimens even
though the blister packages were verified on return vis-
its. Similarly, some of the side effects may have been
missed during the early stages of their occurrence.
Although SP failures seem to be high in the studies
related here in, it is still administered to pregnant
women as Intermittent Preventive Therapy in pregnancy
as part of antenatal care, with the assumption that SP is
still efficacious in this adult population with better
immunity than in children under 5 years of age. These
findings provide useful information for the Ministry of
Health, which is recommending amodiaquine-artesunate
as first-line treatment of uncomplicated malaria in
Cameroon [24], amid fears that it will cause weakness
and other side effects. Artesunate+Amodiaquine either
as a co-blister or a fixed dose combination (ASAQ),
show very high efficacy and tolerability in Cameroon
and elsewhere [25-27], negating fears that the ACTs are
likely to demonstrate late failures if the component drug
(AQ) is already failing.
A high level of resistance mutations was found in the
pfcrt and dhfr genes in keeping with the reduced in
vivo sensitivity found to AQ and SP. However, a lower
prevalence of resistance markers to pfcrt and pfmdr1
was found in the northern part of the country than in
the south but, not matched by significant drop in in
vivo efficacy. This may be as a result of many factors
including greater drug pressure or parasite mixing in
the south due to higher transmission intensity than in
the dryer north. The genetic structure of parasite in
Cameroon may be different from the rest of Africa and
further studies are certainly needed especially as the
parasites donated to an Africa-wide study of parasite
dispersal phenomenon in Africa demonstrated that
parasites from Cameroon were one of five types and
different form the other four types found in North
East, South East, South West and West Africa [16].
These findings suggest that in circumstances of varia-
tions across the continent or sub-regions, a different
kind of drug policy may be needed, probably embra-
cing multiple first line therapies rather than a one
drug-strategy-fits-all approach. Studies of molecular
markers can help to map local differences in drug
resistance [16]. The continuous mapping of the pat-
terns of resistance mutations to important anti-malar-
ials can be used as an early warning system for
therapeutic profiles occurring in endemic areas, leading
to discussions on possible changes in drug policy. In
conclusion, the high prevalence of pfcrt, pfmdr1, dhfr
and dhps mutations and their association with high
failure rates in-vivo to SP, AQ and the combination
SPAQ supports the recommendation by the govern-
ment of Cameroon in changing its first-line treatment
away from monotherapies in favour of artemisinin-
based combination therapy and established the baseline
for mutations to be monitored over time.
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